N2OFF (NXTS)
Develops mitochondrial transporter drug candidates and European solar and storage projects.
Something off on this page? Send us feedback.
Uses MITOLINE™ to discover drug candidates for mitochondrial transport proteins while developing European solar and battery-storage projects. Both reportable segments remain pre-revenue, with biotechnology at a preclinical stage and projects intended for sale or longer-term operation.
Uses MITOLINE™ to model mitochondrial membrane transport proteins and screen molecules for drug candidates. The biotechnology activity, conducted through wholly owned MitoCareX Bio in Ness Ziona, focuses on an undisclosed transporter in cancers and inflammatory metabolic diseases. Its discovery work has selected a hit compound for hit-to-lead medicinal chemistry, but has no approved products, completed preclinical or clinical trials, product revenue, or sales capability.
Develops solar and battery-storage projects in Europe through NITO Renewable Energy and Solterra-related arrangements. The renewable model contemplates selling projects as they advance from land identification and development through construction, while potentially retaining some for longer-term operation.
Both reportable segments remain pre-revenue. The biotechnology activity has no manufacturing facility and would depend on third-party manufacturers if a candidate advances.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $8.9M · Total debt $426.0K · Total assets $18.7M · Shareholders' equity $1.9M
- Revenue
- $0
- Operating income
- −$1.6M
- Net income
- −$11.1M
No dividends on record.
| Institutions | 4.36% | 63.4K shares | |
|---|---|---|---|
| 6 holders · as of Jun 30, 2026 | |||
| Insiders | 4.71% | 68.5K shares | |
| 1 holder · as of Mar 26, 2026 | |||
| Other | 90.93% | 1.32M shares | |
| remainder | |||
1.45M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (1.45M in the company's Sep 22, 2026 report, 56.6K elsewhere); stakes use the report.
A stock split fell inside the quarter, so quarter-on-quarter changes are not shown.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Eun Young Lee1Insider10 percent owner | 4.71% | 68,503 | filed Mar 26, 2026 |
HRT Financial LPInstitution | 3.11% | 45,240 | as of Jun 30, 2026 |
Yorkville Advisors Global, LPInstitution | 1.13% | 16,409 | as of Jun 30, 2026 |
Vanguard Fiduciary Trust CoInstitution | 0.07% | 998 | as of Jun 30, 2026 |
Tower Research Capital LLC (TRC)Institution | 0.05% | 736 | as of Jun 30, 2026 |
- Reported at 3.23% on Jul 15, 2026, under the 5% line, so no further filing is required.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jan 29, 2026 | Eun Young Lee | 10 percent owner | −127 | $1.36 |
- Relay Therapeutics
Computational–experimental small-molecule discovery platform rival.
- Schrödinger
Physics-plus-AI molecular discovery platform rival.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| N2OFF | $1.39 | +1.04% | $78.1K | — | — | — | −77.8% |
| Relay Therapeutics | $18.73 | +2.99% | $3.99B | — | — | 385.1 | −48.3% |
| Schrödinger | $30.61 | +1.21% | $2.26B | — | — | 8.7 | +7.5% |
| Median | — | — | 196.9 | −20.4% |